WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
What a blast to work at NASA. Space agency is sky
Rodeo bullfighter wrangles three zebras on the loose in Washington
Jerry Seinfeld says 'extreme left' politically correct mob has killed comedy
Mexican officials regret US decision not to retry American rancher in fatal shooting of Mexican man
Who is Jacob Zuma, the former South African president disqualified from next week's election?
Climate change could virtually disappear in Florida — at least according to state law
Rapper Quavo is mercilessly mocked after only a handful of fans turn up for Connecticut show
The Yellowstone effect! House prices in these rural Wyoming towns have soared to an all
Tamara Ecclestone is criticised as her daughter Fifi, 10, heads out wearing heavy make
Cardinals rally to beat Tigers 2
Seven sneaky clauses in estate agent contracts that can cost you dear
Lawmakers and advocates make last